This article was published on July 10, 2022. It was last updated on July 11, 2022. Semaglutide injection (Wegovy™) is a glucagon-like peptide-1 (GLP-1) receptor agonist that is given as a once-weekly subcutaneous injection for “chronic weight management” in specified subgroups of patients (see FDA indications below). It was approved by the FDA in 2021…